Get started
Author

Lise M Verhoef

Observed names: L Verhoef, L. M. Verhoef, L.M. Verhoef, LM Verhoef, Lise M. Verhoef, Lise Verhoef, Verhoef, L.M., Verhoef, Lise, Verhoef, Lise M.
ORCID: 0000-0002-9740-5607
Observed ORCID: 0000-0002-9740-5607
OpenAlex ID: A5057545573
Social Media and Rating Sites as Tools to Understanding Quality of Care: A Scoping Review
2014 · Lise M Verhoef, Tom H Van de Belt, et al. · Journal of Medical Internet Research · 130
PDF
Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity
2019 · Lise M Verhoef, Bart JF van den Bemt, et al. · Cochrane Database of Systematic Reviews · 82
PDF
bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search
2017 · Lise M. Verhoef, Lieke Tweehuysen, et al. · Rheumatology and Therapy · 52
PDF
Is the role as gatekeeper still feasible? A survey among Dutch general practitioners
2014 · J. J. G. Wammes, P. P. T. Jeurissen, et al. · Family Practice · 52
Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review
2021 · C. A. J. Michielsens, M. E. van Muijen, et al. · Drugs · 51
PDF
The disciplined healthcare professional: a qualitative interview study on the impact of the disciplinary process and imposed measures in the Netherlands
2015 · Lise M Verhoef, Jan-Willem Weenink, et al. · BMJ Open · 48
PDF
Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial
2019 · Lise M Verhoef, Nathan den Broeder, et al. · The Lancet Rheumatology · 38
Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial
2022 · Celia AJ Michielsens, Nathan den Broeder, et al. · Annals of the Rheumatic Diseases · 35
PDF
Using Patient Experiences on Dutch Social Media to Supervise Health Care Services: Exploratory Study
2015 · Tom H van de Belt, Lucien JLPG Engelen, et al. · Journal of Medical Internet Research · 34
PDF
The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study
2018 · Lise M Verhoef, Ellen M H Selten, et al. · Lara D. Veeken · 32
PDF
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study
2023 · Céleste J T van der Togt, Bart Van den Bemt, et al. · RMD Open · 28
PDF
Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial
2017 · Alfons A. den Broeder, Lise M. Verhoef, et al. · Trials · 23
Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study
2021 · Celia A J Michielsens, Nathan den Broeder, et al. · Lara D. Veeken · 22
PDF
Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial
2020 · Celia A. J. Michielsens, Nadine Boers, et al. · Trials · 21
PDF
Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review
2022 · Maike H M Wientjes, Alfons A den Broeder, et al. · RMD Open · 18
PDF
Construct validity of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) treatment target cut-offs in a BASDAI treat-to-target axial spondyloarthritis cohort: a cross-sectional study
2023 · CAJ Michielsens, TE Bolhuis, et al. · Scandinavian Journal of Rheumatology · 15
PDF
Effect of metformin use on clinical outcomes and serum urate in gout patients with diabetes mellitus: a retrospective cohort study
2022 · Frouwke Veenstra, Lise M. Verhoef, et al. · BMC Rheumatology · 14
PDF
Cost-effectiveness of five different anti-tumour necrosis factor tapering strategies in rheumatoid arthritis: a modelling study
2019 · LM Verhoef, DPG Bos, et al. · Scandinavian Journal of Rheumatology · 14
Drug levels, anti-drug antibodies and B-cell counts were not predictive of response in rheumatoid arthritis patients on (ultra-)low-dose rituximab
2022 · Maike H M Wientjes, Titia M G Gijzen, et al. · Lara D. Veeken · 13
Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells
2022 · Merel A A Opdam, J H de Leijer, et al. · Lara D. Veeken · 12
PDF
Rheumatologists' guideline adherence in rheumatoid arthritis: a randomised controlled study on electronic decision support, education and feedback.
2018 · Nienke Lesuis, Ronald F van Vollenhoven, et al. · PubMed · 12
Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study
2023 · Lara D Veeken, Merel A A Opdam, et al. · Lara D. Veeken · 9
PDF
Sex differences in response to allopurinol and benzbromarone in gout: a retrospective cohort study
2021 · Frouwke Veenstra, Sophie A C Wanten, et al. · Rheumatology Advances in Practice · 9
Preferences of Patients With Musculoskeletal Disorders Regarding the Timing and Channel of eHealth and Factors Influencing Its Use: Mixed Methods Study
2023 · Jeffrey van der Ven, Bart J F van den Bemt, et al. · JMIR Human Factors · 8
PDF
The pharmacological and clinical aspects behind dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs): rationale and systematic narrative review of clinical evidence
2020 · Gerlienke E. Geurts-Voerman, Lise M. Verhoef, et al. · BMC Rheumatology · 8
PDF
Works count: 103
Citation count: 884
H-index: 15
I10-index: 21
Year
Topic
Type